The 'n-factors' in pancreatic cancer: Functional relevance of NF-κB, NFAT and Nrf2 in pancreatic cancer

Oncogenesis

Volumn 1, Issue 11, 2012, Pages

  Arlt, A ^a   Schafer H ^a   Kalthoff, H ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Apoptosis; Chemoresistance; Pancreatic cancer; Signal transduction; Transcription factor

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NRF2;

CANCER CELL; CANCER CHEMOTHERAPY; CANCER RESISTANCE; DRUG POTENCY; ELECTROPHILIC STRESS; GENE TARGETING; HISTONE ACETYLATION; HUMAN; IMMUNOCOMPETENT CELL; LIFE EXPECTANCY; NUCLEAR LOCALIZATION SIGNAL; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PANCREAS ADENOCARCINOMA; POINT MUTATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; REVIEW; T LYMPHOCYTE ACTIVATION; TRANSACTIVATION; TUMOR SUPPRESSOR GENE;

EID: 84893155306     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2012.35     Document Type: Review

References (146)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. Cancer statistics 2008. CA Cancer J Clin 2008;58:71-96.
2. Hidalgo M. Pancreatic cancer. N Engl J Med 2010;362:1605-1617.
3. Remmers N, Bailey JM, Mohr AM, Hollingsworth MA. Molecular pathology of early pancreatic cancer. Cancer Biomark 2010;9:421-440.
4. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet 2011;378:607-620.
5. Aichler M, Seiler C, Tost M, Siveke J, Mazur PK, Da Silva-Buttkus P et al. Origin of pancreatic ductal adenocarcinoma from atypical flat lesions: a comparative study in transgenic mice and human tissues. J Pathol 2012;226:723-734.
6. Arlt A, Muerkoster SS, Schafer H. Targeting apoptosis pathways in pancreatic cancer. Cancer Lett (e-pub ahead of print 13 November 2010; doi:10.1016/j.canlet.2010.10.015).
7. Vulfovich M, Rocha-Lima C. Novel advances in pancreatic cancer treatment. Expert Rev Anticancer Ther 2008;8:993-1002.
8. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-1825.
9. Saif MW, Chabot J. Chemotherapy: metastatic pancreatic cancer-is FOLFIRINOX the new standard? Nat Rev 2011;8:452-453.
10. Saif MW. New developments in the treatment of pancreatic cancer. Highlights from the "44th ASCO Annual Meeting". Chicago, IL, USA. May 30 - June 3, 2008. JOP 2008;9:391-397.
11. Shi S, Yao W, Xu J, Long J, Liu C, Yu X. Combinational therapy: new hope for pancreatic cancer? Cancer Lett 2012;317:127-135.
12. Ji B, Tsou L, Wang H, Gaiser S, Chang DZ, Daniluk J et al. Ras activity levels control the development of pancreatic diseases. Gastroenterology 2009;137:1072-1082.
13. Van den Eynde M, Baurain JF, Mazzeo F, Machiels JP. Epidermal growth factor receptor targeted therapies for solid tumours. Acta Clin Belg 2011;66:10-17.
14. Vaccaro V, Melisi D, Bria E, Cuppone F, Ciuffreda L, Pino MS et al. Emerging pathways and future targets for the molecular therapy of pancreatic cancer. Expert Opin Ther Targets 2011;15:1183-1196.
15. Fukushige S, Horii A. Road to early detection of pancreatic cancer: Attempts to utilize epigenetic biomarkers. Cancer Lett (e-pub ahead of print 23 March 2012; doi:10.1016/j.canlet.2012.03.022).
16. Schuler S, Fritsche P, Diersch S, Arlt A, Schmid RM, Saur D et al. HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells. Mol Cancer 2010;9:80.
17. Roder C, Trauzold A, Kalthoff H. Impact of death receptor signaling on the malignancy of pancreatic ductal adenocarcinoma. Eur J Cell Biol 2011;90:450-455.
18. Chaturvedi MM, Sung B, Yadav VR, Kannappan R, Aggarwal BB. NF-kappaB addiction and its role in cancer: 'one size does not fit all'. Oncogene 2011;30:1615-1630.
19. Perkins ND. The diverse and complex roles of NF-kappaB subunits in cancer. Nat Rev Cancer 2012;12:121-132.
20. Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat Immunol 2011;12:715-723.
21. Wang SJ, Gao Y, Chen H, Kong R, Jiang HC, Pan SH et al. Dihydroartemisinin inactivates NF-kappaB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo. Cancer Lett 2010;293:99-108.
22. Jennewein C, Karl S, Baumann B, Micheau O, Debatin KM, Fulda S. Identification of a novel pro-apoptotic role of NF-kappaB in the regulation of TRAIL- and CD95-mediated apoptosis of glioblastoma cells. Oncogene 2011;31:1468-1474.
23. Martin AG. NFkappaB anti-apoptotic or pro-apoptotic, maybe both. Cell Cycle 2010;9:3131-3132.
24. Hamacher R, Schmid RM, Saur D, Schneider G. Apoptotic pathways in pancreatic ductal adenocarcinoma. Mol Cancer 2008;7:64.
25. Chen PH, Yang CR. Decoy receptor 3 expression in AsPC-1 human pancreatic adenocarcinoma cells via the phosphatidylinositol 3-kinase-, Akt-, and NF-kappa B-dependent pathway. J Immunol 2008;181:8441-8449.
26. Lemke J, Noack A, Adam D, Tchikov V, Bertsch U, Roder C et al. TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5. J Mol Med 2010;88:729-740.
27. Trauzold A, Wermann H, Arlt A, Schutze S, Schafer H, Oestern S et al. CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-kappaB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells. Oncogene 2001;20:4258-4269.
28. Trauzold A, Roder C, Sipos B, Karsten K, Arlt A, Jiang P et al. CD95 and TRAF2 promote invasiveness of pancreatic cancer cells. Faseb J 2005;19:620-622.
29. Khanbolooki S, Nawrocki ST, Arumugam T, Andtbacka R, Pino MS, Kurzrock R et al. Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. Mol Cancer Ther 2006;5:2251-2260.
30. Braeuer SJ, Buneker C, Mohr A, Zwacka RM. Constitutively activated nuclear factor-kappaB, but not induced NF-kappaB, leads to TRAIL resistance by upregulation of X-linked inhibitor of apoptosis protein in human cancer cells. Mol Cancer Res 2006;4:715-728.
31. Trauzold A, Siegmund D, Schniewind B, Sipos B, Egberts J, Zorenkov D et al. TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene 2006;25:7434-7439.
32. Shah SA, Potter MW, McDade TP, Ricciardi R, Perugini RA, Elliott PJ et al. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem 2001;82:110-122.
33. Arlt A, Gehrz A, Muerkoster S, Vorndamm J, Kruse ML, Folsch UR et al. Role of NFkappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 2003;22:3243-3251.
34. Arlt A, Vorndamm J, Breitenbroich M, Folsch UR, Kalthoff H, Schmidt WE et al. Inhibition of NF-kappaB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene 2001;20:859-868.
35. Kiefel H, Bondong S, Erbe-Hoffmann N, Hazin J, Riedle S, Wolf J et al. L1CAMintegrin interaction induces constitutive NF-kappaB activation in pancreatic adenocarcinoma cells by enhancing IL-1beta expression. Oncogene 2010;29:4766-4778.
36. Kong R, Sun B, Jiang H, Pan S, Chen H, Wang S et al. Downregulation of nuclear factor-kappaB p65 subunit by small interfering RNA synergizes with gemcitabine to inhibit the growth of pancreatic cancer. Cancer Lett 2010;291:90-98.
37. Melisi D, Xia Q, Paradiso G, Ling J, Moccia T, Carbone C et al. Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. J Natl Cancer Inst 2011;103:1190-1204.
38. Porta C, Riboldi E, Sica A. Mechanisms linking pathogens-associated inflammation and cancer. Cancer Lett 2011;305:250-262.
39. Uomo I, Miraglia S, Pastorello M. Inflammation and pancreatic ductal adenocarcinoma: a potential scenario for novel drug targets. JOP 2010;11:199-202.
40. Garcea G, Dennison AR, Steward WP, Berry DP. Role of inflammation in pancreatic carcinogenesis and the implications for future therapy. Pancreatology 2005;5:514-529.
41. Arlt A, Vorndamm J, Muerkoster S, Yu H, Schmidt WE, Folsch UR et al. Autocrine production of interleukin 1beta confers constitutive nuclear factor kappaB activity and chemoresistance in pancreatic carcinoma cell lines. Cancer Res 2002;62:910-916.
42. Niu J, Li Z, Peng B, Chiao PJ. Identification of an autoregulatory feedback pathway involving interleukin-1alpha in induction of constitutive NF-kappaB activation in pancreatic cancer cells. J Biol Chem 2004;279:16452-16462.
43. Zhou DH, Trauzold A, Roder C, Pan G, Zheng C, Kalthoff H. The potential molecular mechanism of overexpression of uPA, IL-8, MMP-7 and MMP-9 induced by TRAIL in pancreatic cancer cell. Hepatobiliary Pancreat Dis Int 2008;7:201-209.
44. Kurbitz C, Heise D, Redmer T, Goumas F, Arlt A, Lemke J et al. Epicatechin gallate and catechin gallate are superior to epigallocatechin gallate in growth suppression and anti-inflammatory activities in pancreatic tumor cells. Cancer Sci 2011;102:728-734.
45. Treiber M, Neuhofer P, Anetsberger E, Einwachter H, Lesina M, Rickmann M et al. Myeloid, but Not Pancreatic, RelA/p65 Is Required for Fibrosis in a Mouse Model of Chronic Pancreatitis. Gastroenterology 2011;141:e1477.
46. Rachagani S, Senapati S, Chakraborty S, Ponnusamy MP, Kumar S, Smith LM et al. Activated KrasG (1) (2) D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin. Br J Cancer 2011;104:1038-1048.
47. Maier HJ, Wagner M, Schips TG, Salem HH, Baumann B, Wirth T. Requirement of NEMO/IKKγ for effective expansion of KRAS-induced precancerous lesions in the pancreas. Oncogene. (e-pub ahead of print 2 July 2012; doi:10.1038/onc.2012.272).
48. Ling J, Kang Y, Zhao R, Xia Q, Lee DF, Chang Z et al. KrasG12D-induced IKK2/beta/NF-kappaB activation by IL-1alpha and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell 2012;21:105-120.
49. Chiao PJ, Ling J. Kras, Pten, NF-kappaB, and inflammation: dangerous liaisons. Cancer Discov 2011;1:103-105.
50. Li Y, Vandenboom 2nd TG, Wang Z, Kong D, Ali S, Philip PA et al. miR-146a suppresses invasion of pancreatic cancer cells. Cancer Res 2010;70:1486-1495.
51. Liptay S, Weber CK, Ludwig L, Wagner M, Adler G, Schmid RM. Mitogenic and antiapoptotic role of constitutive NF-kappaB/Rel activity in pancreatic cancer. Int J Cancer 2003;105:735-746.
52. Zhang H, Ma G, Dong M, Zhao M, Shen X, Ma Z et al. Epidermal growth factor promotes invasiveness of pancreatic cancer cells through NF-kappaB-mediated proteinase productions. Pancreas 2006;32:101-109.
53. Banerjee S, Wang Z, Kong D, Sarkar FH. 3, 3'-Diindolylmethane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer. Cancer Res 2009;69:5592-5600.
54. Greten FR, Weber CK, Greten TF, Schneider G, Wagner M, Adler G et al. Stat3 and NF-kappaB activation prevents apoptosis in pancreatic carcinogenesis. Gastroenterology 2002;123:2052-2063.
55. Infante JR, Jones SF, Bendell JC, Spigel DR, Yardley DA, Weekes CD et al. A phase I, dose-escalation study of pomalidomide (CC-4047) in combination with gemcitabine in metastatic pancreas cancer. Eur J Cancer 2011;47:199-205.
56. Liu WM, Nizar S, Dalgleish AG. Gemcitabine and lenalidomide combination in a patient with metastatic pancreatic cancer: a case study. Med Oncol 2010;27:430-433.
57. Shan YS, Lin PW. A phase I study of combination of intravenous gemcitabine, oxaliplatin, and 5-FU with daily oral thalidomide (GOFT) in metastatic/locally advanced pancreatic carcinoma patients. Hepatogastroenterology 2007;54:2141-2145.
58. Lo M, Ling V, Low C, Wang YZ, Gout PW. Potential use of the anti-inflammatory drug, sulfasalazine, for targeted therapy of pancreatic cancer. Curr Oncol 2010;17:9-16.
59. Muerkoster S, Arlt A, Witt M, Gehrz A, Haye S, March C et al. Usage of the NFkappaB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer. Int J Cancer 2003;104:469-476.
60. Lee DF, Hung MC. Advances in targeting IKK and IKK-related kinases for cancer therapy. Clin Cancer Res 2008;14:5656-5662.
61. Nogueira L, Ruiz-Ontanon P, Vazquez-Barquero A, Moris F, Fernandez-Luna JL. The NFkappaB pathway: a therapeutic target in glioblastoma. Oncotarget 2011;2:646-653.
62. Lin Y, Bai L, Chen W, Xu S. The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy. Expert Opin Ther Targets 2010;14:45-55.
63. Ramaswamy B, Bekaii-Saab T, Schaaf LJ, Lesinski GB, Lucas DM, Young DC et al. A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 2010;66:151-158.
64. Arlt A, Bauer I, Schafmayer C, Tepel J, Muerkoster SS, Brosch M et al. Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2). Oncogene 2009;28:3983-3996.
65. Lenz HJ. Clinical update: proteasome inhibitors in solid tumors. Cancer Treat Rev 2003;29(Suppl 1):41-48.
66. Hoeller D, Dikic I. Targeting the ubiquitin system in cancer therapy. Nature 2009;458:438-444.
67. Kanai M, Yoshimura K, Asada M, Imaizumi A, Suzuki C, Matsumoto S et al. A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother Pharmacol 2011;68:157-164.
68. Wang Z, Desmoulin S, Banerjee S, Kong D, Li Y, Deraniyagala RL et al. Synergistic effects of multiple natural products in pancreatic cancer cells. Life Sci 2008;83:293-300.
69. Shanmugam MK, Nguyen AH, Kumar AP, Tan BK, Sethi G. Targeted inhibition of tumor proliferation, survival, and metastasis by pentacyclic triterpenoids: Potential role in prevention and therapy of cancer. Cancer Lett 2012;320:158-170.
70. Banerjee S, Kaseb AO, Wang Z, Kong D, Mohammad M, Padhye S et al. Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer. Cancer Res 2009;69:5575-5583.
71. Rausch V, Liu L, Kallifatidis G, Baumann B, Mattern J, Gladkich J et al. Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics. Cancer Res 2010;70:5004-5013.
72. Lampe JW. Sulforaphane: from chemoprevention to pancreatic cancer treatment? Gut 2009;58:900-902.
73. Kallifatidis G, Rausch V, Baumann B, Apel A, Beckermann BM, Groth A et al. Sulforaphane targets pancreatic tumour-initiating cells by NF-kappaB-induced antiapoptotic signalling. Gut 2009;58:949-963.
74. Konig A, Fernandez-Zapico ME, Ellenrieder V. Primers on molecular pathways-the NFAT transcription pathway in pancreatic cancer. Pancreatology 2010;10:416-422.
75. Baumgart S, Ellenrieder V, Fernandez-Zapico ME. Oncogenic transcription factors: cornerstones of inflammation-linked pancreatic carcinogenesis. Gut (e-pub ahead of print 13 October 2011; doi:10.1136/gutjnl-2011-301008).
76. Mancini M, Toker A. NFAT proteins: emerging roles in cancer progression. Nat Rev Cancer 2009;9:810-820.
77. Nayak A, Glockner-Pagel J, Vaeth M, Schumann JE, Buttmann M, Bopp T et al. Sumoylation of the transcription factor NFATc1 leads to its subnuclear relocalization and interleukin-2 repression by histone deacetylase. J Biol Chem 2009;284:10935-10946.
78. Yoeli-Lerner M, Chin YR, Hansen CK, Toker A. Akt/protein kinase b and glycogen synthase kinase-3beta signaling pathway regulates cell migration through the NFAT1 transcription factor. Mol Cancer Res 2009;7:425-432.
79. Jauliac S, Lopez-Rodriguez C, Shaw LM, Brown LF, Rao A, Toker A. The role of NFAT transcription factors in integrin-mediated carcinoma invasion. Nat Cell Biol 2002;4:540-544.
80. Baumgart S, Glesel E, Singh G, Chen NM, Reutlinger K, Zhang J et al. Restricted heterochromatin formation links NFATc2 repressor activity with growth promotion in pancreatic cancer. Gastroenterology 2012;142:e381-e387.
81. Singh SK, Baumgart S, Singh G, Konig AO, Reutlinger K, Hofbauer LC et al. Disruption of a nuclear NFATc2 protein stabilization loop confers breast and pancreatic cancer growth suppression by zoledronic acid. J Biol Chem 2011;286:28761-28771.
82. Koenig A, Linhart T, Schlengemann K, Reutlinger K, Wegele J, Adler G et al. NFATinduced histone acetylation relay switch promotes c-Myc-dependent growth in pancreatic cancer cells. Gastroenterology 2010;138:e1181-e1182.
83. +/calcineurin signaling pathway. EMBO J 2006;25:3714-3724.
84. Medyouf H, Ghysdael J. The calcineurin/NFAT signaling pathway: a novel therapeutic target in leukemia and solid tumors. Cell Cycle 2008;7:297-303.
85. Shibasaki F, Hallin U, Uchino H. Calcineurin as a multifunctional regulator. J Biochem 2002;131:1-15.
86. Marcen R. Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection. Drugs 2009;69:2227-2243.
87. Zheng J, Fang F, Zeng X, Medler TR, Fiorillo AA, Clevenger CV. Negative cross talk between NFAT1 and Stat5 signaling in breast cancer. Mol Endocrinol 2011;25:2054-2064.
88. Padilla PI, Chang MJ, Pacheco-Rodriguez G, Adamik R, Moss J, Vaughan M. Interaction of FK506-binding protein 13 with brefeldin A-inhibited guanine nucleotide-exchange protein 1 (BIG1): effects of FK506. Proc Natl Acad Sci USA 2003;100:2322-2327.
89. Cooper JE, Wiseman AC. Novel immunosuppressive agents in kidney transplantation. Clin Nephrol 2010;73:333-343.
90. Nguyen T, Nioi P, Pickett CB. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem 2009;284:13291-13295.
91. Martin-Montalvo A, Villalba JM, Navas P, de Cabo R. NRF2, cancer and calorie restriction. Oncogene 2011;30:505-520.
92. Tian H, Zhang B, Di J, Jiang G, Chen F, Li H et al. Keap1: One stone kills three birds Nrf2, IKKbeta and Bcl-2/Bcl-xL. Cancer Lett 2012;325:26-34.
93. Hayes JD, McMahon M. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem Sci 2009;34:176-188.
94. Osburn WO, Kensler TW. Nrf2 signaling: an adaptive response pathway for protection against environmental toxic insults. Mutat Res 2008;659:31-39.
95. Lau A, Villeneuve NF, Sun Z, Wong PK, Zhang DD. Dual roles of Nrf2 in cancer. Pharmacol Res 2008;58:262-270.
96. Wang XJ, Sun Z, Villeneuve NF, Zhang S, Zhao F, Li Y et al. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis 2008;29:1235-1243.
97. Singh A, Wu H, Zhang P, Happel C, Ma J, Biswal S. Expression of ABCG2 (BCRP) is regulated by Nrf2 in cancer cells that confers side population and chemoresistance phenotype. Mol Cancer Ther 2010;9:2365-2376.
98. Pickering AM, Linder RA, Zhang H, Forman HJ, Davies KJ. Nrf2-dependent induction of proteasome and Pa28alphabeta regulator are required for adaptation to oxidative stress. J Biol Chem 2012;287:10021-10031.
99. Sebens S, Bauer I, Geismann C, Grage-Griebenow E, Ehlers S, Kruse ML et al. Inflammatory macrophages induce Nrf2 transcription factor-dependent proteasome activity in colonic NCM460 cells and thereby confer anti-apoptotic protection. J Biol Chem 2011;286:40911-40921.
100. Hu Y, Ju Y, Lin D, Wang Z, Huang Y, Zhang S et al. Mutation of the Nrf2 gene in non-small cell lung cancer. Mol Biol Rep 2011;39:4743-4747.
101. Kim YR, Oh JE, Kim MS, Kang MR, Park SW, Han JY et al. Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin. J Pathol 2010;220:446-451.
102. Eades G, Yang M, Yao Y, Zhang Y, Zhou Q. miR-200a regulates Nrf2 activation by targeting Keap1 mRNA in breast cancer cells. J Biol Chem 2011;286:40725-40733.
103. Kinch L, Grishin NV, Brugarolas J. Succination of Keap1 and Activation of Nrf2-Dependent Antioxidant Pathways in FH-Deficient Papillary Renal Cell Carcinoma Type 2. Cancer Cell 2011;20:418-420.
104. Nioi P, Nguyen T. A mutation of Keap1 found in breast cancer impairs its ability to repress Nrf2 activity. Biochem Biophys Res Commun 2007;362:816-821.
105. Wang R, An J, Ji F, Jiao H, Sun H, Zhou D. Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues. Biochem Biophys Res Commun 2008;373:151-154.
106. Akhdar H, Loyer P, Rauch C, Corlu A, Guillouzo A, Morel F. Involvement of Nrf2 activation in resistance to 5-fluorouracil in human colon cancer HT-29 cells. Eur J Cancer 2009;45:2219-2227.
107. DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 2011;475:106-109.
108. Hong YB, Kang HJ, Kwon SY, Kim HJ, Kwon KY, Cho CH et al. Nuclear factor (erythroid-derived 2)-like 2 regulates drug resistance in pancreatic cancer cells. Pancreas 2010;39:463-472.
109. Jiang T, Chen N, Zhao F, Wang XJ, Kong B, Zheng W et al. High levels of Nrf2 determine chemoresistance in type II endometrial cancer. Cancer Res 2010;70:5486-5496.
110. Kim TH, Hur EG, Kang SJ, Kim JA, Thapa D, Lee YM et al. NRF2 blockade suppresses colon tumor angiogenesis by inhibiting hypoxia-induced activation of HIF-1alpha. Cancer Res 2011;71:2260-2275.
111. Kim SK, Yang JW, Kim MR, Roh SH, Kim HG, Lee KY et al. Increased expression of Nrf2/ARE-dependent anti-oxidant proteins in tamoxifen-resistant breast cancer cells. Free Radic Biol Med 2008;45:537-546.
112. Konstantinopoulos PA, Spentzos D, Fountzilas E, Francoeur N, Sanisetty S, Grammatikos AP et al. Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer. Cancer Res 2011;71:5081-5089.
113. Lister A, Nedjadi T, Kitteringham NR, Campbell F, Costello E, Lloyd B et al. Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy. Mol Cancer 2011;10:37.
114. Singh A, Misra V, Thimmulappa RK, Lee H, Ames S, Hoque MO et al. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med 2006;3:e420.
115. Solis LM, Behrens C, Dong W, Suraokar M, Ozburn NC, Moran CA et al. Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res 2010;16:3743-3753.
116. Kim J, Cha YN, Surh YJ. A protective role of nuclear factor-erythroid 2-related factor-2 (Nrf2) in inflammatory disorders. Mutat Res 2010;690:12-23.
117. Sebens S, Bauer I, Geismann C, Grage-Griebenow E, Ehlers S, Kruse ML et al. Inflammatory macrophages induce NRF2 dependent proteasome activity in colonic NCM460 cells and thereby confer anti-apoptotic protection. J Biol Chem 2011;286:40911-40921.
118. Singh S, Vrishni S, Singh BK, Rahman I, Kakkar P. Nrf2-ARE stress response mechanism: a control point in oxidative stress-mediated dysfunctions and chronic inflammatory diseases. Free Radic Res 2010;44:1267-1288.
119. Du ZX, Yan Y, Zhang HY, Liu BQ, Gao YY, Niu XF et al. Proteasome inhibition induces a p38 MAPK pathway-dependent antiapoptotic program via Nrf2 in thyroid cancer cells. J Clin Endocrinol Metab 2011;96:E763-E771.
120. Singh A, Bodas M, Wakabayashi N, Bunz F, Biswal S. Gain of Nrf2 function in nonsmallcell lung cancer cells confers radioresistance. Antioxid Redox Signal 2010;13:1627-1637.
121. Keum YS. Regulation of the Keap1/Nrf2 system by chemopreventive sulforaphane: implications of posttranslational modifications. Ann NY Acad Sci 2011;1229:184-189.
122. Zhao CR, Gao ZH, Qu XJ. Nrf2-ARE signaling pathway and natural products for cancer chemoprevention. Cancer Epidemiol 2010;34:523-533.
123. Lee JS, Surh YJ. Nrf2 as a novel molecular target for chemoprevention. Cancer Lett 2005;224:171-184.
124. Wang XJ, Hayes JD, Henderson CJ, Wolf CR. Identification of retinoic acid as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha. Proc Natl Acad Sci USA 2007;104:19589-19594.
125. Zhou W, Lo SC, Liu JH, Hannink M, Lubahn DB. ERRbeta: a potent inhibitor of Nrf2 transcriptional activity. Mol Cell Endocrinol 2007;278:52-62.
126. Arlt A, Sebens S, Krebs S, Geismann C, Grossmann M, Kruse ML et al. Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased proteasomal gene expression and proteasome activity. Oncogene. (e-pub ahead of print 29 October 2012; doi:10.1038/onc.2012.493).
127. Gupta S, Pramanik D, Mukherjee R, Campbell NR, Elumalai S, de Wilde RF et al. Molecular determinants of retinoic acid sensitivity in pancreatic cancer. Clin Cancer Res 2012;18:280-289.
128. Tang X, Wang H, Fan L, Wu X, Xin A, Ren H et al. Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs. Free Radic Biol Med 2011;50:1599-1609.
129. Boettler U, Sommerfeld K, Volz N, Pahlke G, Teller N, Somoza V et al. Coffee constituents as modulators of Nrf2 nuclear translocation and ARE (EpRE) - dependent gene expression. J Nutr Biochem 2011;22:426-440.
130. Lee S, Lim MJ, Kim MH, Yu CH, Yun YS, Ahn J et al. An effective strategy for increasing the radiosensitivity of Human lung Cancer cells by blocking Nrf2-dependent antioxidant responses. Free Radic Biol Med 2012;53:807-816.
131. Serfling E, Berberich-Siebelt F, Avots A, Chuvpilo S, Klein-Hessling S, Jha MK et al. NFAT and NF-kappaB factors-the distant relatives. Int J Biochem Cell Biol 2004;36:1166-1170.
132. 2+ influx on TNF-alpha-induced COX-2-dependent prostaglandin E2 production in human colonic myofibroblasts. Am J Physiol Gastrointest Liver Physiol 2011;301:G356-G367.
133. Cai T, Li X, Ding J, Luo W, Li J, Huang C. A cross-talk between NFAT and NFkappaB pathways is crucial for nickel-induced COX-2 expression in Beas-2B cells. Curr Cancer Drug Targets 2011;11:548-559.
134. Fu L, Lin-Lee YC, Pham LV, Tamayo A, Yoshimura L, Ford RJ. Constitutive NFkappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas. Blood 2006;107:4540-4548.
135. Telliez A, Furman C, Pommery N, Henichart JP. Mechanisms leading to COX-2 expression and COX-2 induced tumorigenesis: topical therapeutic strategies targeting COX-2 expression and activity. Anticancer Agents Med Chem 2006;6:187-208.
136. Jendrossek V. Targeting apoptosis pathways by Celecoxib in cancer. Cancer Lett (e-pub ahead of print 21 February 2011; doi:10.1016/j.canlet.2011.01.012).
137. Lipton A, Campbell-Baird C, Witters L, Harvey H, Ali S. Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer. J Clin Gastroenterol 2010;44:286-288.
138. Li W, Khor TO, Xu C, Shen G, Jeong WS, Yu S et al. Activation of Nrf2-antioxidant signaling attenuates NFkappaB-inflammatory response and elicits apoptosis. Biochem Pharmacol 2008;76:1485-1489.
139. Jiang J, Mo ZC, Yin K, Zhao GJ, Lv YC, Ouyang XP et al. Epigallocatechin-3-gallate prevents TNF-alpha-induced NF-kappaB activation thereby upregulating ABCA1 via the Nrf2/Keap1 pathway in macrophage foam cells. Int J Mol Med 2012;29:946-956.
140. Yeang HX, Hamdam JM, Al-Huseini LM, Sethu S, Djouhri L, Walsh J et al. Loss of transcription factor nuclear factor-erythroid 2 (NF-E2) p45-related factor-2 (Nrf2) leads to dysregulation of immune functions, redox homeostasis, and intracellular signaling in dendritic cells. J Biol Chem 2012;287:10556-10564.
141. Wakabayashi N, Slocum SL, Skoko JJ, Shin S, Kensler TW. When NRF2 talks, who's listening? Antioxid Redox Signal 2010;13:1649-1663.
142. Kim JE, You DJ, Lee C, Ahn C, Seong JY, Hwang JI. Suppression of NF-kappaB signaling by KEAP1 regulation of IKKbeta activity through autophagic degradation and inhibition of phosphorylation. Cell Signal 2010;22:1645-1654.
143. Yu M, Li H, Liu Q, Liu F, Tang L, Li C et al. Nuclear factor p65 interacts with Keap1 to repress the Nrf2-ARE pathway. Cell Signal 2011;23:883-892.
144. Wang S, Penchala S, Prabhu S, Wang J, Huang Y. Molecular basis of traditional Chinese medicine in cancer chemoprevention. Curr Drug Discov Technol 2010;7:67-75.
145. Goel A, Aggarwal BB. Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer 2010;62:919-930.
146. Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci 2008;65:1631-1652.